Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
7 evidence topics · 5 sources
Anticipated population: patients aged 2 years and older
Care setting: one-time outpatient intrathecal administration
Payer research: value proposition of a one-time outpatient administration
Route of administration: intrathecal lumbar compared with intracerebroventricular delivery
“Administration route strongly influences biodistribution: ICV delivery (NGN-401) provides broad brain penetration but requires neurosurgery, whereas intrathecal lumbar injection (TSHA-102) is less invasive but may yield more limited forebrain distribution.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ICV delivery requires neurosurgical placement of a catheter into the lateral ventricle” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Role of neurologists and specialized centers
“As these therapies progress toward potential regulatory approval, neurologists will play central roles in identifying eligible patients, counseling families, supporting clinical trial enrollment, delivering treatments, monitoring long-term outcomes, and advocating for equitable access.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Access is further constrained by the need for specialized centers capable of administering therapy and monitoring for complications, disproportionately affecting families in rural areas, underserved communities, and low-income countries.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote